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Abstract
Rationale Lithium, some of the anticonvulsants, and several
second-generation antipsychotic drugs are common medi-
cations widely prescribed to treat bipolar disorder. Molecular
targets and cellular events that mediate their effects have
been described for these drugs but are only partially
unraveled. Few comparative studies have been performed.
Objectives We evaluated seven mood stabilizers (MS) in
the same in vitro system and found several differences and
similarities in their cellular mechanisms (proliferation and
cell survival). As some MS were previously shown to
activate the Akt/GSK-3β axis, this pathway was explored
for other drugs.
Materials and methods The SH-SY5Y cells were cultured
in RPMI-1640 medium. Effects of MS drugs on serum-
induced cell proliferation and on slowing of cell death were
analyzed. Phosphorylation and expression of Akt-1 and
GSK-3β mRNA and protein were assessed for the seven
drugs as well.
Results Lithium, Valproate, Olanzapine, and Clozapine
enhance proliferation and protect cells against serum
withdrawal-induced injury. These drugs also activate Akt-
1 and GSK-3β phosphorylation. Interestingly, gene expres-
sion of Akt-1 mRNA and protein, but not GSK-3β, was
increased. The other drugs Lamotrigine, Haloperidol, and
Carbamazepine did not affect cellular events nor activate
Akt/GSK-3β axis.
Conclusion Valproate and atypical antipsychotics (Olanzapine
and Clozapine) regulate SH-SY5Y cell proliferation and
survival, activate the Akt/GSK-3β axis, and stimulate gene
expression of Akt-1 mRNA and protein, as does Lithium. The
other medications have no effect. The study shows the
importance of the Akt/GSK-3 axis in MS actions but also
pinpoints a different dependence of these drugs on this
signaling axis.
Keywords Mood stabilizers . SH-SY5Y cell proliferation .
Neuroprotection . Akt–GSK-3β . Signaling axis
Introduction
Lithium and some anticonvulsant drugs such as Lamotri-
gine (Ltg) or Valproate (VPA) are common medications
prescribed to treat patients with bipolar disorder symptom-
atology and to prevent relapses (Aubry et al. 2007; Yatham
et al. 2006). Recently, some atypical antipsychotics such as
olanzapine (Ola) or clozapine (CZ) have also been
considered as mood stabilizers (MS) to prevent manic and
depressive episodes (Brambilla et al. 2003; Yatham et al.
2005). All these medications are recommanded by official
guidelines. Regarding conventional antipsychotics such as
Haloperidol (Hal), although they have a therapeutic effect
in manic episode, a prophylactic effect on relapse preven-
tion has not been shown for this class of medication
(Gelenberg and Hopkins 1996). Because bipolar disorder
and other psychiatric illness are associated with changes in
volume of discrete brain regions, there is much interest in
potential neurotrophic effects of treatments (Sheline 2003;
Psychopharmacology (2009) 205:419–429
DOI 10.1007/s00213-009-1551-2
M. Schwald : E. Ballmann : F. Karege (*)
Department of Medical Genetics,
Geneva University Hospitals and Geneva University,
Chemin Petit Bel-Air, 2,
CH-1225 Chêne-Bourg, Switzerland
e-mail: felicien.karege@unige.ch
J.-M. Aubry
Department of Psychiatry, Bipolar Program, Geneva University
Hospitals and University of Geneva,
6-8 rue du 31 Décembre,
CH-1207 Geneva, Switzerland
Manji and Duman 2001). Furthermore, recent research has
shown interest in how mood-stabilizing agents change the
activities of signal transduction systems (Chen et al. 1999;
Manji and Duman 2001). Our study has focused on cellular
events and on protein kinases (Akt-1 and GSK-3β)
involved in signaling axes in order to compare effects of
different classes of mood stabilizers.
Lithium, the standard mood stabilizer drug, has emerged
as a neuroprotective agent against insult and apoptotic
stimuli (for review, Jope and Bijur 2002; Manji et al. 1999;
Jope and Williams 1994; Li and El-Mallahk 2000). It has
also been reported that long-term lithium treatment
increases total gray matter volume (Moore et al. 2000).
This cation is involved in a number of biochemical systems
and tens of enzymatic activities and signal transduction
systems, including the inositol monophosphatase, the
phospholipase C, adenylate cyclase, and protein kinase C
(for review, Manji et al. 1999). Lithium has been shown to
be a direct inhibitor of glycogen synthase kinase (GSK-3β),
a serine/threonine-specific protein kinase that plays key
roles in the regulation of a variety of cellular processes
(Klein and Melton 1996; Stambolic et al. 1996). GSK-3β is
regulated upstream by another protein kinase, Akt-1, and
together these two kinases are part of a signaling pathway
regulated by both phosphatidylinositide 3-kinase (PI3K;
Cross et al. 1995; Grimes and Jope 2001) and by the Wnt
signal (Zeng et al. 2005). Akt and GSK-3β proteins are
involved in cell cycle progression, cell survival, neuronal
structure, and apoptotic cell death (Lawlor and Alessi 2001;
Jope and Johnson, 2004). There is both direct and indirect
evidence supporting the involvement of these proteins in
the pathophysiology of mood disorders and schizophrenia
(Lesort et al. 1999; Hsiung et al. 2003; Karege et al. 2007;
Pandey et al. 2009; Beaulieu et al. 2009).
Some of the other drugs of the above-mentioned list, but
not all, have been shown to affect these cellular and
biochemical changes. Olanzapine produces trophic effects
in vitro and stimulates a number of signal transduction such
as Akt, ERK, and the mitogen-activated protein kinase p38
(Lu et al. 2004). Moreover, Olanzapine was shown to
enhance glucose uptake consistent with that neurotrophic
role (Dwyer et al. 2003). Valproate is also known to have
diverse cellular effects, such as protecting against apoptotic
insults, although this has been suggested to be cell-type-
specific (Chen et al. 1999; Chuang 2005). Valproate was
initially reported to inhibit GSK-3β activity in SH-SY5Y
cells, but these effects in neuronal cells have not been
confirmed by all authors (Gurvich and Klein 2002).
Clozapine is an atypical or second-generation antipsychotic
drug sometimes used in treatment-resistant bipolar disorder
and proposed as a mood stabilizer (Ciapparelli et al. 2003).
This drug was reported to regulate the phopshorylation of
GSK-3β through the Wnt signal mechanism (Kang et al.
2004). For the other drugs, like Lamotrigine, Carbamaze-
pine, or Haloperidol, few studies have been carried out
either on cell survival or on potentiation of cell proliferation
(Xie and Hagan, 1998). With respect to the Akt/GSK-3β
pathway, Haloperidol effect has been examined in rat
frontal cortex (Roh et al. 2007). The authors indicated that
haloperidol induces transiently both Ser-21/9 phosphoryla-
tion of GSK-3βα/β and Ser-473 phosphorylation of Akt,
but no study on long-term expression of these proteins was
performed in their protocol. Moreover, few studies have
compared the effects of these drugs in the same conditions
and on the same cellular model. This approach could help
to identify shared mechanisms between drugs.
Therefore, the aim of this study was to compare different
classes of mood stabilizers and explore possible differences
or shared mechanisms in their biochemical effects on the
Akt/GSK-3β signaling pathways. As bipolar disorder is
associated with changes in structures of some discrete brain
regions, there is much interest in the neurotrophic effects of
MS. To determine possible effects of these drugs, cells were
grown at low serum content (LSC, 5%). Moreover, as
bipolar disorder may be due in part to alterations in signal
transduction mechanisms, activation and expression of the
Akt-1 and GSK-3β protein were assessed. These proteins
exist in different forms (Akt-1, Akt-2, Akt-3, and GSK-3α,
GSK-3β, respectively). For this study, we have chosen to
study Akt-1 and GSK-3β because they are more ubiqui-
tously expressed at high levels than the other isoforms.
Furthermore, phosphorylation at serine473-Akt-1 and
serine9-GSK-3β, which are the major physiologic mecha-
nisms to activate these proteins, was used to assess rapid
drug actions. The Akt/GSK-3β pathway is an important
axis in neural plasticity. A better understanding of these
processes may result in identification of therapeutically
important sites of actions for the development of novel
mood-stabilizing drugs.
Materials and methods
Drugs and reagents
All drugs (Lithium Chloride, Valproate, Haloperidol,
Carbamazepine, Lamotrigine, Clozapine) and other
reagents used (i.e., LY294002) were purchased from Sigma
(St Louis, MO, USA). Olanzapine was a gift from Eli Lilly
and Co. (Indianapolis, IN, USA).
Cell culture and drug treatment: assessment of proliferation
and cell survival
The human-derived neuroblastoma cells, the SH-SY5Y,
purchased from ECACC (Salisbury, UK), were cultured in
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a humidified atmosphere of 95% air/5% CO2 at 37°C in
RPMI-1640 medium supplemeted with 10% (v/v) fetal calf
serum supplemented with 100 U/ml penicillin and 100μg/
ml streptomycin (Invitrogen, Basel, CH). Depending on the
experiment, cells were plated at various densities on
100-mm dishes or six-well plates, and where indicated,
serum was withdrawn 24 h or few hours before adding the
drugs. For the proliferation test, cells grown in the low fetal
calf serum (FCS; 5%) medium were plated at the same
density and incubated up to 72 h with different drugs. In
preliminary tests, different drug levels were used in dose–
response assays, but only optimal drug doses (1 mM
lithium, 0.6 mM VPA, 10μM clozapine) were used in
different experiments. Cells were counted in each
24-h period to determine their proliferation. For the survival
study, cells were seeded at 105 cells/well in a six-well plate
in serum-free RPMI-1640, and the drugs were added. Two
controls without drugs (serum-free and serum-feed medi-
um) were performed. The medium and drugs were changed
every 2 to 3 days, and fresh drugs were added. Phase-
contrast images were acquired from three random fields
from three coverslips at different times up to 10 days, and
cells were counted. Cell viability was assessed by the
trypan blue staining method and further confirmed by the 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) method
(Kahle and Maas 1997).
Biochemical assays
Concentration–response and time course effects of different
drugs, namely Lithium, Valproate, Carbamazepine, and
Lamotrigine, as well as of typical and atypical antipsychot-
ic, Haloperidol, Olanzapine, and Clozapine, on the Akt-1
and GSK-3β were analyzed. The range of drug concen-
trations was chosen from either the previous in vitro
studies, therapeutic doses, or human plasma levels when
known (Bowden et al. 1994 and 1996; Perry et al. 1998;
Ciapparelli et al. 2000; Aubry et al. 2007; Kim et al. 2008;
Heiser et al. 2007). Concentration range of Lamotrigine and
Carbamazepine correspond roughly to the therapeutic
windows used in bipolar disorder treatment (Calabrese et
al. 2008; Simhandl et al. 1993). Both immediate effects
(473Ser-Akt and 9Ser-GSK-3β phosphorylation) and late
biochemical actions (Akt-1 and GSK-3β proteins and
mRNA expression) were determined. In some experiments,
blockade of PI3K pathway was performed by prior addition
of 20μM LY2920049, a specific inhibitor of the pathway.
Protein assay by Western immunoblot
All proteins were determined by the Western immunoblot
method as previously described in detail (Karege et al.
2007). Cells were homogenized in a lysis buffer (50 mM
Tris pH7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium
decolate, 0.1% sodium dodecyl sulfate (SDS), 5 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, aprotinin,
leupeptin, and pepstatin (10μg/ml each). Homogenates
were incubated for 20 min at 4°C with shaking, centrifuged
(10,000×g for 10 min, 4°C), and the supernatant was used
for the assay samples. The loading buffer contained
0.125 mM Tris (pH6.8), 20% glycerol, 10% mercaptoetha-
nol, 4% SDS, and 0.02% bromophenol blue. Samples were
heated at 95°C for 10 min before gel loading. Protein
concentrations had previously been determined using the
BCA kit (Pearse Chemical, Rockford, USA). Equal
amounts of a soluble fraction of cell proteins (25μg for
GSK-3β or Akt and β-actin or 50μg for ser9-pGSK-3β and
473ser-pAkt) were electrophoresed on 10% (w/v ratio) SDS-
polyacrylamide gel with a Mini Protean system (Bio Rad)
with molecular weight standards. After electrophoresis, the
samples were electrotransferred overnight onto nitrocellu-
lose membranes (GE Amersham) then blocked for 1 h at
room temperature in Tris-buffered saline Tween-20 solution
with 5% (w/v) non-fat milk powder and bovine serum
albumin, 2%. The blots were incubated overnight at 4°C
with primary antibody for Akt-1 (1:1,000) or phospho-Akt
(1:500) purchased from either Cell Signaling Technology
(Beverly, MA, USA), or Santa-Cruz Technology (Santa
Cruz, CA, USA). After washing, membranes were incubat-
ed with an anti-rabbit IgG labeled with HRP (Amersham
Pharmacia) for 1 h at room temperature. The membranes
were washed and developed with the ECLWestern Blotting
system (Amersham Pharmacia) followed by exposure of the
membranes with radiographic films (Hyperfilm ECL,
Amersham Pharmacia). In most cases, the membranes were
stripped with Reprob Plus (Chemicon, Temecula, CA,
USA) and reincubated with β-actin antibody (1:1,000
dilution; Abcam Ltd. Cambridge, UK) as the reference
protein. Quantification of the immunoreactivities was
performed by densitometric scanning using an image
analysis system (Molecular Analyst, BioRad). The optical
density (OD) obtained from each band was normalized
against the corresponding β-actin band.
Total RNA extraction and quantitative reverse transcription
polymerase chain reaction
Approximately 5×106 cells were collected after different
periods of drug treatment, washed in phosphate-buffered
saline, and then submitted to lysis with the RNAqueous kit
from Ambion (Austin, TX, USA). Total RNA concentration
was determined from a spectrophotometer optical density
measurement ( 260 and 280 nm), and the purity of RNA
was tested on a Bioanalyzer Agilent Technologies instru-
ment (Basel, CH) which yield two sharp bands of 18 S and
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28 S RNA. For all samples tested, the ratio between the
spectrophotometer readings at 260 and 280 nm (OD 260/
OD 280) was between 1.8 and 2.0. Reverse transcription
reactions were carried out on 500 ng of total RNA using the
High Capacity cDNA Archive enzyme (Applied Biosys-
tems) at 37°C for 2 h.
For real-time reverse transcription polymerase chain
reaction (RT-PCR), the ABI Prism 7900 HT Sequence
Detection System instrument and the Assay-on-demands
Gene Expression Products (TaqMan MGB probes, FAM
dye-labeled) from Applied Biosystems (Applera Europe,
Rotkreuz) were used to quantify mRNA for target gene and
endogenous controls (β-actin or glyceraldehyde-3-
phosphate dehydrogenase (GAPDH)). The thermal condi-
tions were given by the supplier : an initial step (2 min at
50°C and 10 min at 95°C) was followed by 40 cycles of
amplification (15 s at 95°C and 1 min at 60°C). All samples
were run in triplicate. Data were analyzed by the SDS 2.2
software with the comparative Ct method, where mRNA
levels of target genes were normalized to the corresponding
β-actin or GAPDH gene expression (Livak and Schmittgen
2001). The drug-naive treated samples at time 0 h were
used as calibrator samples, and results were expressed in
percentage of change with respect to control.
Statistical analyses
Statistical analyses were performed with a statistical
software (StatView V, Brain Power, Calabasas, CA, USA).
Data from immunoblotting and from quantitative RT-
PCR (qRT-PCR) were expressed in relative values
(percentages or ratios ± SD) with respect to housekeep-
ing genes (GAPDH or β-actin). Due to transformed
values, nonparametric Friedman tests for analysis of
variance (ANOVA) was used for variance between
groups, and multiple comparisons between was per-
formed with post hoc Mann–Whitney U test. The
significance was set at p<0.05.
Results
Cell proliferation and cell survival
Cellular effects of different mood stabilizers were assessed
in serum-fed (proliferating cells) and serum-deprived
(dying cells) neuroblastoma cells, by applying different
doses of mood stabilizers. To reveal possible effects of
these drugs, cells were grown at low serum content (LSC,
5%). Figure 1a, b displays a concentration–response study
with different mood stabilizer drugs. Only Lithium,
Valproate (Fig. 1a), and Olanzapine (Fig. 1b) significantly
potentiated serum-induced cell proliferation in a dose–
response manner. For the other drugs, there was either no
change or decrease in cell proliferation (high concentrations
induced toxicity). The doses with optimal responses were
used to assess the time-course effects. Li+ (1 mM), VPA
(0.6 mM), and Ola (25μM) gradually increased cell
proliferation both at 24 and 48 h. At 72 h, cells were in a
confluence state, both in controls and MS-treated samples
(Fig. 2a, b), and the effect of drugs was nulled. The
withdrawal of serum induced a progressive death (Fig. 3),
and application of drugs on cell cultures prevented or
delayed cell death. Lithium, Valproate, Clozapine (Fig. 3a,
b), and Ola (Fig. 3c) significantly delayed the cell death.
The other drugs (Lamotrigine, Carbamazepine, and Hala-
peridol) were unable to prevent cell death (Fig. 3c)
Phosphorylation of Akt-1 and GSK-3β proteins
A study of immediate effects on the phosphorylation of Akt
at serine-473 and GSK-3β serine-9 was performed (Fig. 4),
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Fig. 1 Concentration–response effect of mood stabilizer on cell
proliferation on SH-SY5Y cells cultured in RPMI-1640 with low
serum content (LSC, 5% FCS) and complemented with mood
stabilizers for a period of 24 h. a Lithium, Valproate, and Clozapine
and b Olanzapine, Lamotrigine, Haloperidol, and Carbamazepine.
Results are expressed in percentage changes of controls (no drug
added to LSC), and data are mean values (±SD) of four to six
independent assays. Nonparametric Mann–Whitney tests: *p<0.05;
**p<0.01
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and result showed that addition of Lithium (1 mM),
Valproate (0.6 mM), and Olanzapine (25μM) to LSC-
grown samples activated GSK-3β and Akt-1 phosphoryla-
tion after 30 min. There was also a late activation by
Clozapine (not shown), and no other drug did activate the
Akt/GSK-3β. Respective t tests on both GSK-3β and Akt
were for Lithium (p<0.05 and 0.01, respectively), for
Valproate (p<0.01 and 0.01, respectively), and for Olanza-
pine (p<0.01 and 0.01, respectively). Addition of
LY294002 (20μM), a specific PI3K inhibitor, 10 min
before drug application, resulted in decrease or suppression
of the Akt-1 phosphorylation in both Lithium (1 mM) and
Olanzapine (50μM)-treated cells with respective to LSC
samples (data not shown).
Akt-1 gene expression (mRNA and protein levels)
Figure 5a, b displays data of the real-time qRT-PCR for
Akt-1 gene expression. Lithium and Valproate (Fig. 5a) and
Olanzapine (Fig. 5b) induced a time-dependent increase in
Akt mRNA levels (Friedman test of ANOVA: χ2=19.8 p<
0.01, χ2=20.2; p<0.01, and χ2=21.6, p<0.01, respective-
ly). These changes were significant after 12 h for Lithium
(p<0.05), Valproate (p<0.01), and Olanzapine (p<0.01)
and progressively increased at 18 and 24 h. For the
Clozapine-treated cells, the global changes were not
significant, but at 24 h, Akt-1 mRNA was significantly
increased compared with control levels (p<0.05). No
change was observed in GSK-3β mRNA during the same
period, whatever the drug used (data not shown).
Analysis of total Akt-1 and total GSK-3β proteins
over a period of 72 h of drug treatment revealed that Akt
protein levels, but not GSK-3β protein, significantly
increased compared to control levels (time—0 h;
Fig. 6b, c). Friedman test of ANOVA yielded for Akt
changes: χ2=13.5; p<0.05. Multiple comparison analysis
indicated that changes were significant after 24 h for
Lithium, Valproate, and Olanzapine (p<0.05). A weak
change was also observed for Clozapine but at 48 h (p<
0.05; Fig. 6b). No change in GSK-3β protein levels was
observed during this period.
Discussion
The major goal of the present study was to determine whether
anticonvulsant molecules or typical and atypical antipsychotic
drugs could induce cellular effects and regulate molecular
pathways, namely the Akt/GSK-3β axis, with comparable
efficacy and timing with those of Lithium (Fig. 7). Seven
different drugs, most of them used as mood stabilizers, were
analyzed in vitro by investigating both cellular and biochem-
ical actions on cultures of SH-SY5Y cells. The potentiation
of cell proliferation and the blockade of cell death were also
assessed. Phosphorylation of both Akt-1 and GSK-3β
protein kinases and expression of mRNA and proteins were
analyzed as well. The study yielded the following results:
1. On the cellular level, the low serum content stimulates
the cell division and proliferation at a steady pace.
Addition of the mood stabilizers to the culture medium
results in significant potentiation. The effect was
statistically significant after 24 h (Lithium, Olanzapine,
and Valproate) and 48 h (Clozapine). In these conditions,
the other drugs (Lamotrigine, Carbamazepine, and
Haloperidol) have no effect on the proliferation.
The withdrawal of serum initiates the apoptotic cell death.
Addition of some mood stabilizers (Li+, VPA, CZ, and Ola)
in the serum-free cell culture protects cells by a transient
proliferation and a delayed death allowing them to survive a
few more days. Lamotrigine, Carbamazepine, and Haloper-
idol have no effect on the survival of SH-SY5Y cells.
2. On the molecular level, after 30 min, Lithium,
Olanzapine, and Valproate induced a significant phos-
phorylation of 9Ser-GSK-3β and 473Ser-Akt-1, com-
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Fig. 2 Time-course study of mood stabilizer effects on cell
proliferation. a Li+, VPA, and CZ. b Ltg, Cbz, Hal, and Ola. Results
which show relative growth are expressed in percent of control values
(LSC cells). Data are mean values (s ± SD) of four to six independent
assays. Nonparametric Mann–Whitney tests: *p<0.05; **p<0.01
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pared with LSC-feed controls. The other drugs did not
induce any phosphorylation activity. The effect of these
drugs was prevented by a previous application of a
PI3K inhibitor (20μM LY294002), confirming that
Akt-1 was activated through PI3K signaling. At 12 h,
Lithium, Olanzapine, and Valproate induced an in-
crease in Akt-1 mRNA levels, compared with LSC
samples. No such change was observed for GSK-3β
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Fig. 3 The neuroprotective effect of mood stabilizers against serum
withdrawal-induced cell death. Viable cells were counted in serum-
deprived medium where mood stabilizer drugs were supplemented. a
Contrast images of SH-SH5Y cells in different conditons of culture. b
Serum-free cells with addition of 1 mM Li+, 0.6 mM VPA, or 25μM
CZ. c Serum-free cells with addition of 100μM Ltg, 50μM Cbz,
50μM Hal, or 25μM Ola. Results are mean values (±SD) of four to
six independent assays. In both figures, control cases with 10% FCS-
feed and serum-free cells are shown. With respect to serum-free
samples, significant differences were found at 48 (Li+, VA, and CZ, p
<0.05) and at 24, 48, and 72 h (Ola, p<0.05)
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mRNA. Clozapine effect on Akt mRNAwas significant
after 24 h, and the other drugs did not induce any
change in mRNA levels. After 24 h, increase in Akt-1
protein levels, but not in GSK-3β levels, was observed
in Lithium-, Olanzapine-, and Valproate-treated cells.
Clozapine effect was significant after 48 h, and no
other drug was observed to be effective. After these
observations, Lamotrigine, Haloperidol, and Carbama-
zepine's effects on these cell paradigms were null.
Globally, these data are in accordance with a number of
previous individual reports especially the phosphorylation
of Akt and GSK-3β and the cellular events here studied (Di
Daniel et al. 2005; Kang et al. 2004; Li et al. 2002; Manji
and Duman 2001; Kozlovsky et al. 2006). However, we
were unable to find a study investigating all these
medications in a single protocol. Di Daniel compared the
action of four MS drugs (VPA, Li+, Cbz, and Ltg) but on a
different signaling axis, i.e. ERK/MAPK. Moreover, these
authors did not include a typical antipsychotic drug, such as
Haloperidol (Di Daniel et al. 2005). Using animal brain,
Kozlovsky et al. (2006) have analyzed the effect of four
drugs (VPA, CZ, Hal, and Li+) on the in vivo phosphor-
ylation of GSK-3β and reported similar data. However,
they did not test the MS effect on Akt-1 activation. Many
other important studies were carried out using either one
drug or compared two or three drugs, mostly Ola, CZ, VPA,
and Li+ (Kim et al. 2008; Heiser et al. 2007).
The novelty of this study consists in three points: first,
for the first time, seven different MS drugs were used to test
two cell events (proliferation and survival) and three
molecular assays (protein phosphorylation, mRNA, and
protein expression) on two important biochemical actors,
Akt-1 and GSK-3β. To our knowledge, no other previous
assay has tested a so complex mechanism. Second, to our
knowledge, no other study has been conducted on the
Carbamazepine or Lamotrigine's effects on Akt/GSK-3β
pathway. And thirdly, for the first time, we report an
increase of the Akt-1 mRNA and protein levels by mood
stabilizers. The latter point is the most important result of
this study, given the importance of Akt-1 protein in the
proliferation processes.
Previous works conducted on animal and neuronal and
non-neuronal cells have suggested that psychotropic drugs,
including Lithium, Valproate, or other antipsychotics, can
enhance cell viability and activate the Akt/GSK-3β
signaling pathway (Li and El-Mallahk 2000; Di Daniel et
al. 2005; Kang et al. 2004; Manji and Duman 2001;
Kozlovsky et al. 2006). However, Shin et al. reported a
different effect of CZ with an inhibition of Akt and a
dephosphorylation of GSK-3β (Shin et al. 2006). But as
they admitted themselves, they used a special cell line, the
U-87MG glioblastoma, a cell which lacks a powerful
regulator of the Akt/GSK-3β axis, the PTEN, and probably
mobilizes alternative pathways.
With respect to Carbamazepine, this drug was reported
to be involved in signal transduction of cyclic adenosine
monophosphate (cAMP) second messenger systems, but no
effect on Akt/GSK-3β has been reported up to date (Gould
et al. 2004). Lamotrigine has a potent activity dependent on
ion channels (i.e., Na+ and Ca+) and could have indirect
action on signal transduction (Xie and Hagan 1998).
Whether Ltg has direct actions on this intracellular
signaling molecules has not been extensively studied to
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Fig. 4 Effect of mood stabilizer drugs on phosphorylation of 473S-
Akt-1 and 9S-GSK-3β. a Representative Western blot images. b Cells
were treated with Li+, VPA, or CZ. c Cells were treated with Ltg, Cbz,
Hal, and Ola. Relative values of optical densities (ROD) of 9S-pGSK-
3β and 473S-pAkt immunoblots expressed as percent of nontreated
samples. Data are mean values (±SD) of four to six independent
assays, and statistical analysis with t test yielded significant change in
different samples. Nonparametric Mann–Whitney tests were: *p<0.05
and **p<0.01
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date. Also, both Haloperidol and Clozapine were shown to
induce GSK-3β phosphorylation, but as this study was
conducted in rat brain cortex, it could be thought that the
effect depends on the cell type (Roh et al. 2007).
Interestingly, Akt protein levels, but not GSK-3β, were
gradually increased in parallel to the drug-induced cell
proliferation. It seems that the two molecular and cellular
processes have a causal relationship. A number of previous
reports have demonstrated that Akt is not only involved in
cell growth but is also involved in glucose metabolism/
uptake (Hajduch et al. 2001; Lawlor and Alessi 2001). Akt
was shown to be a key mediator of signal transduction
process and mediates many of the survival signals (Brunet
et al. 2001). Therefore, it is possible to speculate that the
addition of the mood-stabilizing drugs resulted in inducing
more Akt protein levels available for signals that mediate
the subsequent cell proliferation. Valproate was the most
effective on enhancing Akt-1 protein levels. This effect
could be alternatively explained by its capacity to upregu-
late gene expression through inhibiting histone-deacetylase,
as has been reported (Harwood and Agam 2003; De Sarno
et al. 2002).
Our study showed that cellular events and protein
synthesis were preceded by rapid phosphorylation and
mRNA synthesis. This may suggest that long-term effects
must probably be previously sensitized by acute effects,
such as protein phosphorylation and mRNA synthesis. To
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Fig. 6 Time-course of mood stabilizer drugs on Akt-1 protein levels
in SH-SY5Y cells grown in LSC medium supplemented with mood
stabilizers at their respective optimal doses. Proteins were assayed by
the Western immunoblot method, and results are relative optical
densities (ROD). a Represntative Western blot images. b Li+, VPA,
and CZ. c Ltg, Cbz, Hal, and Ola. Data, expressed as percent of
change with respect to controls, are means (±SD) of four to six
independent assays. Nonparametric Mann–Whitney tests were signif-
icant: *p<0.05; **p<0.01
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Fig. 5 Time course of Akt-1 mRNA expression in SH-SY5Y cells
grown in LSC medium supplemented with mood stabilizers at their
respective optimal doses. Akt-1 mRNA was assayed by the real-time
quantitative RT-PCR method, and results were expressed in ratio
values with respect to a house-keeping gene (i.e., GAPDH). a Li+,
VPA, and CZ at optimal levels. b Ltg, Cbz, Hal, and Ola. Data,
expressed as percent of change with respect to controls, are mean
values (±SD) of four to six independent assays. Friedman test of
ANOVA: χ2=19.8, p<0.01; χ2=20.2, p<0.01; and χ2=21.6, p<0.01,
respectively. Post hoc nonparametric Mann–Whitney tests were
significant: *p<0.05; **p<0.01
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reveal this sequential process, the use of cells with high
rates of division such as SH-SY5Y could be an advantage.
Globally, our results indicate that cellular mechanisms
observed with Lithium are shared by Valproate, Clozapine,
and Olanzapine but not by Carbamazepine, Lamotrigine,
and Haloperidol. This could suggest that either the SH-
SY5Y cell is not a universal model to investigate these cell
events or that the MS drug effects are cell-type-specific.
Moreover, all drugs do not activate the Akt/GSK-3β. This
indicates that this signaling pathway is not shared by all
mood stabilizers.
This study raised some points which require more
clarification. First, comparison to clinical situations was
allowed by performing at optimal concentrations which
correspond nearly to their therapeutically relevant concen-
trations as reported by different authors (Bowden et al.
1994 and 1996; Perry et al. 1998; Ciapperelli et al. 2003;
Aubry et al. 2007). However, the doses used for Olanzapine
were higher than the corresponding clinical doses (Olesen
and Linnet 1999). The serum concentrations are usually
much lower, but according to some authors, the brain levels
can contain much higher doses of Olanzapine (Olesen and
Linnet 1999; Robertson and McMullin 2000; Lu et al.
2004). This is probably due to the fact that brain cells,
especially fatty cells, can accumulate the drug and reach
levels sufficient to induce the effects observed in this study
(Lu et al. 2004). In addition, active metabolites can also
contribute to raise the effective concentration of the drug.
This is the case for haloperidol, where postmortem
concentrations were found to be ten to 30 times higher
than the serum concentrations (Kornhuber et al. 1999).
Second, it remains also to clarify the clinical relevance
of such rapid cellular and molecular effect. In clinical
context, these drugs are effective in chronic administration
where after several days they may enhance the resilience of
human neural cells against cell death elicited by diverse
insults (Manji and Duman 2001). The in vitro studies
remain a remote mirror of what really happen in vivo and in
pathological conditions. The increase of Akt-1 gene
expression could be an indication of the MS drugs' effect
to sustain the lag period for onset action.
Another interesting issue concerns the specificity of this
pathway to MS drugs. In other words, do antidepressant
drugs have the same effect? There are few reports on the
effects of antidepressants on either Akt or GSK-3β.
According to Tsai et al. 2008, GSK-3β gene is associated
with antidepressant response in a Chinese population.
Moreover, administration of imipramine and fluoxetine
was found to increase 9S-GSK-3β in mouse brain (Li et
al. 2004). These studies show the importance of this
pathway which can be activated by both mood stabilizers
and antidepressants.
Despite the above-mentioned limitations, this study has
shown that in human-derived neuroblastoma SH-SY5Y
cells, four drugs used as mood stabilizers or antipsychotics,
namely Li+, VPA, Ola, and CZ can mimic the postulated
cellular events occurring in mood disorder. These drugs
were able to delay cell death and therefore to act as
neuroprotectors and to increase serum-induced cell prolif-
eration. The possibility that these drugs may protect cells
from injury-induced death or may enhance growth is
particularly relevant given the reported morphological
deficits associated with bipolar disorder. On a molecular
level, these three drugs activate Akt-1 protein by a rapid
phosphorylation, resulting in deactivating phosphorylation
of GSK-3β. These drugs also induce a time-dependent
increase in Akt-1 gene and protein expression but not in
GSK-3β. The enhanced expression of Akt-1 was parallel to
enhanced cell proliferation, thus confirming its role in anti-
apoptotic processes. This study may suggest that long-term
effects must probably be previously sensitized by acute
effects that only in vitro assays with SH-SY5Ycells can
reveal because of their high rate of division. The study
provides a framework for understanding how protein
kinases involved in signal transduction may contribute to
study MS mechanisms of action.
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